Adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies is associated with improved survival in patients with pelvic lymph node metastasis: a sub-analysis from the COREPEX study

In: International Journal of Gynecological Cancer · 2026 · vol. 36(2) , pp. 103065 · doi:10.1016/j.ijgc.2025.103065 · W7129296227
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
AI-generated summary by claude@2026-06, 2026-06-07

This sub-analysis of the COREPEX study found that adjuvant chemotherapy significantly improved survival outcomes for gynecologic cancer patients who underwent pelvic exenteration and had pelvic lymph node metastasis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-05-13T18:23:01.997123+00:00
License: CC0 · commercial use OK